Jul 09, 2026
By Transpire Insight
Description
According to a research report published by Transpire Insight, the global biologics contract research organizations market size is projected to grow from USD 28.00 billion in 2026 to USD 49.80 billion by 2035, at a CAGR of 10.20% during the forecast period 2026-2035. The market is primarily driven by soaring R&D investments in complex biopharmaceuticals, the geometric growth of clinical trials in oncology and chronic diseases, and a strategic shift by drug sponsors toward flexible, cost-efficient outsourcing models.
Introduction
The global Biologics Contract Research Organizations (CRO) market is expanding rapidly as pharmaceutical and biotech firms increasingly outsource their complex developmental needs. Biologics, derived from living organisms, require highly specialized expertise, sophisticated laboratory infrastructure, and intricate regulatory pathways. To mitigate escalating research and development (R&D) costs and accelerate speed-to-market timelines, drug developers rely on CROs. These specialized partners provide essential end-to-end clinical services, particularly in surging therapeutic areas like oncology, immunology, and advanced cell and gene therapies.
Recent Development News
March 2026: Global CRO leader IQVIA officially unveiled IQVIA.ai at NVIDIA’s GTC conference. Built specifically for life sciences, this unified platform leverages advanced generative AI models and domain-specific infrastructure to automate clinical workflows, extract multimodal research data, and significantly optimize the execution of global clinical trials.
June 2026: At the BIO International 2026 Convention, Thermo Fisher Scientific debuted expanded capabilities across its clinical development and contract services network. The integration featured new AI-enabled research applications and advanced analytical instrumentation designed to streamline drug product pipelines and enhance compliance pathways for complex biological therapies.
Stay Ahead of Emerging Opportunities with Expert Market Insights by Transpire Insight
Transpire Insight provides comprehensive, data-driven market intelligence to support smarter business decisions. Our research is rooted in comprehensive analysis, authoritative predictions, and industry expertise, enabling organizations to make informed decisions in rapidly evolving markets. In-depth analysis of market segmentation, competitive positioning, regional trends, and emerging investment opportunities in high-growth areas. We blend accuracy with actionable intelligence, empowering companies to uncover new avenues for growth, bolster strategic decision-making, and stay ahead in a dynamic global market.
Download the exclusive Biologics Contract Research Organizations Market sample report today to uncover expert insights, emerging trends, and the opportunities defining the future of the industry.
Biologics Contract Research Organizations Market Size & Statistics
Regional Growth and Demand Analysis by Transpire Insight:
North America is expected to grow the fastest during the forecast period in the Biologics Contract Research Organizations market. The dominant player in the Biologics Contract Research Organizations Market is North America, owing to the availability of leading players in terms of biopharmaceutical manufacturing companies, advanced laboratory technology suppliers, and robust investment in medical research. The United States is currently the biggest producer in the Biologics Contract Research Organizations Market, considering factors such as the presence of extensive commercial drug manufacturing operations, efforts toward modernizing clinical trials, and continued advancement in biotechnology engineering. As of 2026, some of the biopharmaceutical companies in the United States have undertaken production activities aimed at manufacturing superior biological products that would enhance next-generation medical treatments.
Asia Pacific is anticipated to generate the highest demand during the forecast period in the Biologics Contract Research Organizations market. It is expected that the Asia-Pacific region will witness the highest growth rate during the forecast period due to increasing demand for healthcare access, growing pipelines of biosimilars, increased therapeutic purchasing programs, and significant investment in medical infrastructure. China, India, Japan, and South Korea are some of the rapidly growing nations regarding biopharmaceutical development activities that drive the demand for advanced contract research technologies. In 2026, there will be an increase in the facility modernization programs by many pharmaceutical companies in China and India. This was done with the aim of ensuring efficient biological testing and clinical research systems.
Top 15 Trends in the Biologics Contract Research Organizations Market
Proceed to Checkout to purchase the exclusive Biologics Contract Research Organizations Market report and gain instant access to in-depth market intelligence, strategic analysis, and future growth opportunities.
Pharmaceutical companies are increasingly delegating biologics research and development to specialized CROs, leveraging external expertise to accelerate drug discovery, clinical trials, and market launches.
AI and data analytics are enhancing CRO services by speeding up patient recruitment, improving trial efficiency, and ensuring greater data accuracy across operations.
Biologics and cell- and gene-therapy pipelines require viral-vector production, ex vivo cell manipulation, and long-term patient monitoring, which most sponsors cannot handle internally.
The adoption of decentralized and digital clinical trials is expanding CRO services by enabling remote patient monitoring and improving recruitment while reducing trial costs.
Mergers and acquisitions are transforming the market as companies seek to broaden service portfolios, access specialized technologies, and expand geographic reach through strategic acquisitions.
As biosimilars pressure legacy revenues, sponsors increasingly lean on CRO partners to supply the highly specialized infrastructure needed for durable gene-editing trials.
Top 25 Companies Leading the Biologics Contract Research Organizations Market
Customize the exclusive Biologics Contract Research Organizations Market report today to receive tailored insights, country-specific analysis, and business-focused market intelligence.
Top 25 Companies Leading the Biologics Contract Research Organizations Market
1. Lonza Group AG
Leading global contract development partner optimizing cell expression systems for biological scaling.
Founded: 1897 | HQ: Basel, Switzerland.
Why It Ranks: Pioneers commercial mammalian cell culture platforms, driving large-scale biological manufacturing dominance.
Regional Dominance: Holds massive market presence, operating advanced network hubs across Europe and North America.
Product line: Mammalian expression systems, microbial therapeutics, bioconjugates, and cell and gene pipelines.
2. WuXi Biologics (WuXi AppTec)
Dominant open-access capability technology platform facilitating end-to-end biological discovery and development.
Founded: 2010 | HQ: Wuxi, China.
Why It Ranks: Accelerates global pipeline development utilizing its massive, high-throughput, integrated single-source infrastructure.
Regional Dominance: Exercises commanding operational leadership throughout Asia-Pacific while aggressively expanding Western facilities.
Product line: Monoclonal antibodies, bispecifics, recombinant proteins, and integrated vaccine development solutions.
3. Samsung Biologics
High-speed contract development engine providing massive bioreactor capacity for global pharmaceutical clients.
Founded: 2011 | HQ: Incheon, South Korea.
Why It Ranks: Unrivaled manufacturing scale and ultra-fast tech transfer capabilities drive elite placement.
Regional Dominance: Anchor market leader in South Korea supporting extensive international export pipelines.
Product line: Large-scale commercial substance manufacturing, biosimilar development, and clinical research coordination.
4. Catalent, Inc.
Premier global formulation partner optimizing delivery technologies across complex macromolecule therapies.
Founded: 2007 | HQ: Somerset, New Jersey, USA.
Why It Ranks: Robust specialized cell therapy networks maximize development efficiency for advanced biotherapeutics.
Regional Dominance: Deeply entrenched market footprint with comprehensive clinical facilities spanning North America.
Product line: Gene therapy vectors, analytical testing services, and specialized fill-finish oral formats.
5. Fujifilm Diosynth Biotechnologies
Advanced microbial and mammalian partner specializing in complex recombinant protein development.
Founded: 1996 | HQ: Tokyo, Japan.
Why It Ranks: Cutting-edge continuous processing innovations optimize yield and purity for biological developers.
Regional Dominance: Multi-site operations secure prominent regulatory and commercial positioning across Western economies.
Product line: Viral vectors, microbial fermentation, monoclonal antibodies, and process cell-line development.
6. AGC Biologics
Global contract partner delivering highly customizable protein expression and plasmid workflows.
Founded: 2001 | HQ: Bothell, Washington, USA.
Why It Ranks: Flexible multi-site capabilities provide seamless operational scaling from clinical to commercial.
Regional Dominance: Balanced operational synergy across integrated facilities in North America, Europe, and Japan.
Product line: Plasmid DNA, messenger RNA platforms, protein therapeutics, and mammalian cell cultures.
7. Thermo Fisher Scientific (Patheon)
End-to-end pharmaceutical services powerhouse matching scientific analytical tools with scalable production.
Founded: 1956 | HQ: Waltham, Massachusetts, USA.
Why It Ranks: Unmatched corporate infrastructure supports clients from initial molecule discovery through commercialization.
Regional Dominance: Unparalleled market penetration leveraging extensive research and logistical networks across North America.
Product line: Clinical trial management, analytical assay validation, sterile packaging, and biosimilar development.
8. Charles River Laboratories
Essential early-stage research partner validating safety and efficacy profiles for biopharmaceuticals.
Founded: 1947 | HQ: Wilmington, Massachusetts, USA
Why It Ranks: Global market leader in critical discovery and preclinical safety testing services.
Regional Dominance: Pervasive footprint anchoring early-stage biotechnology research clusters across the United States.
Product line: Preclinical safety assessments, laboratory models, bioanalysis, and cell therapy sourcing materials.
9. Parexel International
Top-tier clinical trial specialist accelerating international regulatory approvals through decentralized platforms.
Founded: 1982 | HQ: Durham, North Carolina, USA.
Why It Ranks: Deep global regulatory expertise optimizes complex phase trial designs for biologics.
Regional Dominance: Vast worldwide clinical grid displaying exceptional operational strength across North America.
Product line: Phase I-IV trial management, regulatory consulting services, and data management solutions.
10. IQVIA Holdings Inc.
Data-driven clinical research pioneer integrating artificial intelligence with global drug development.
Founded: 1982 | HQ: Durham, North Carolina, USA.
Why It Ranks: Proprietary predictive analytics platforms maximize patient recruitment speed and trial accuracy.
Regional Dominance: Global operational footprint commanding unmatched market analytics share within North America.
Product line: AI-enabled clinical trials, real-world evidence tracking, and commercial outsourcing solutions.
Schedule a meeting with our market experts to discuss the exclusive Biologics Contract Research Organizations Market report and identify the best research solution for your organization.
Conclusion
The global Biologics Contract Research Organizations (CRO) market is positioned for sustained, high-value growth as pharmaceutical developers navigate increasingly complex biological pipelines. Driven by significant R&D investments, advanced cell therapies, and clinical trials across major therapeutic areas, outsourcing remains a critical strategic priority. Leading players like Lonza, WuXi Biologics, and IQVIA continue to expand their integrated technical capabilities and artificial intelligence infrastructure. Ultimately, these specialized CRO partnerships will remain indispensable for driving operational efficiencies, managing rigorous regulatory pathways, and accelerating lifesaver therapeutics to global markets.
Send us a brief description of your challenge and we'll get back to you within 24 hours.
inquiry@transpireinsight.com
APAC:+91 7666513636
Address
